Hunter Gillies Aerovate Therapeutics, Inc. (AVTE) insider trading activity

Hunter Gillies is CHIEF MEDICAL OFFICER of Aerovate Therapeutics, Inc.. Currently has a direct ownership of 5,602 shares of AVTE, which is worth approximately $9,075. The most recent transaction as insider was on Jun 13, 2024, when has been sold 6,000 shares (Common Stock) at a price of $24.5 per share, resulting in proceeds of $147,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.6K

72.32% 3M change

72.32% 12M change

Total Value Held $9,075

Hunter Gillies Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 13 2024	SELL Open market or private sale	$147,000 $24.5 p/Share	6,000 Reduced 51.72%	5,602 Common Stock
Jun 13 2024	BUY Exercise of conversion of derivative security	$12,840 $2.14 p/Share	6,000 Added 34.09%	11,602 Common Stock
May 17 2024	SELL Open market or private sale	$85,880 $21.47 p/Share	4,000 Reduced 41.66%	5,602 Common Stock
May 17 2024	BUY Exercise of conversion of derivative security	$8,560 $2.14 p/Share	4,000 Added 29.41%	9,602 Common Stock
Apr 17 2024	SELL Open market or private sale	$91,280 $22.82 p/Share	4,000 Reduced 55.16%	3,251 Common Stock
Apr 17 2024	BUY Exercise of conversion of derivative security	$6,960 $1.74 p/Share	4,000 Added 35.55%	7,251 Common Stock
Mar 28 2024	SELL Open market or private sale	$265,500 $29.5 p/Share	9,000 Reduced 73.46%	3,251 Common Stock

Mar 28 2024	BUY Exercise of conversion of derivative security	$19,260 $2.14 p/Share	9,000 Added 42.35%	12,251 Common Stock
Mar 18 2024	SELL Open market or private sale	$182,770 $26.11 p/Share	7,000 Reduced 68.29%	3,251 Common Stock
Mar 18 2024	BUY Exercise of conversion of derivative security	$13,580 $1.94 p/Share	7,000 Added 40.58%	10,251 Common Stock
Mar 07 2024	SELL Open market or private sale	$219,887 $24.5 p/Share	8,975 Reduced 73.41%	3,251 Common Stock
Mar 07 2024	BUY Exercise of conversion of derivative security	$19,206 $2.14 p/Share	8,975 Added 42.33%	12,226 Common Stock
Feb 23 2024	SELL Open market or private sale	$9,964 $19.5 p/Share	511 Reduced 13.58%	3,251 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	$889 $1.74 p/Share	511 Added 11.96%	3,762 Common Stock
Feb 20 2024	SELL Open market or private sale	$71,001 $20.35 p/Share	3,489 Reduced 51.77%	3,251 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	$6,070 $1.74 p/Share	3,489 Added 34.11%	6,740 Common Stock
Jan 17 2024	SELL Open market or private sale	$78,000 $19.5 p/Share	4,000 Reduced 55.16%	3,251 Common Stock
Jan 17 2024	BUY Exercise of conversion of derivative security	$6,960 $1.74 p/Share	4,000 Added 35.55%	7,251 Common Stock
Dec 27 2023	SELL Open market or private sale	$3,062 $24.5 p/Share	125 Reduced 3.7%	3,251 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$267 $2.14 p/Share	125 Added 3.57%	3,376 Common Stock
Dec 20 2023	SELL Open market or private sale	$78,000 $19.5 p/Share	4,000 Reduced 55.16%	3,251 Common Stock
Dec 14 2023	SELL Open market or private sale	$192,991 $19.5 p/Share	9,897 Reduced 75.27%	3,251 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	$17,220 $1.74 p/Share	9,897 Added 42.95%	13,148 Common Stock
Dec 13 2023	SELL Open market or private sale	$41,008 $19.5 p/Share	2,103 Reduced 39.28%	3,251 Common Stock
Dec 13 2023	BUY Exercise of conversion of derivative security	$6,960 $1.74 p/Share	4,000 Added 35.55%	7,251 Common Stock

Hunter Gillies

CHIEF MEDICAL OFFICER

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVTE shares.

Notify only if

Value

Insider Trading

Get notified when an Aerovate Therapeutics, Inc. insider buys or sells AVTE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aerovate Therapeutics, Inc.

Track Activities on AVTE

Account